How to Participate in a Cancer Clinical Trial

Below is a list of current trials of cancer treatments at Sharp. Given the technical language, you will probably need more information. If you think you may be interested in any of the trials listed, please consult with your physician or contact the clinical trials manager at 858-939-5062.

The following sites are conducting oncology clinical trials:

The following clinical trials are enrolling patients for the specified treatment areas:

Blood

An open label assessment of safety and efficacy of Ruxolitinib (incb018424) in Subjects with primary myelofibrosis, post essential thrombocythemia-myelofibrosis and post polycythemia vera-myelofibrosis who have platelet counts of 50 x109/L to 100 x109/L

This study is being done to determine the effects of ruxolitinib on spleen volume and symptoms and to learn about any of the side effects that might occur during or following treatment.

Bone Marrow

A Phase 3, Randomized Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma

This study is being done to determine if elotuzumab given with lenalidomide and dexamethasone is more effective at treating relapsed or refractory multiple myeloma compared with the standard treatment of lenalidomide and dexamethasone alone.

A Phase 3, Randomized Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma

This study is being done to determine if elotuzumab given with lenalidomide and dexamethasone is more effective in the initial treatment of multiple myeloma compared with a standard treatment of lenalidomide and dexamethasone alone.

Phase 2, Randomized Study of Bortezomib/dexamethasone With or Without Elotuzumab in Subjects with Relapsed/Refractory Multiple Myeloma

This study is being done to determine if elotuzumab given with bortezomib and dexamethasone is more effective in the treatment of relapsed or refractory multiple myeloma compared with a standard treatment of bortezomib and dexamethasone alone.

A Phase 2 Biomarker Study of Elotuzumab (Humanized anti‑CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma

This study is being done to determine the effectiveness and safety of elotuzumab in patients with high risk smoldering myeloma.

A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles

This study is being done to collect, store, catalog (putting the tissue and data in a tissue bank and data bank for later research purposes) and analyze blood and bone marrow samples and related health information from newly diagnosed multiple myeloma patients and then at different times during their disease.

Breast

ABLATE Registry: Radiofrequency Ablation after Breast Lumpectomy (eRFA) Added to Extend Intraoperative Margins in the Treatment of Breast Cancer

The primary purpose of this study is to examine the effectiveness of creating an area where no cancer cells are found once the primary tumor has been removed using a method called Radiofrequency Ablation (RFA).

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

The purpose of this study is to find out if the Oncotype DX® Recurrence Score can help decide whether patients should receive chemotherapy or not.


A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first-line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive metastatic breast cancer (MBC) who have received trastuzumab and endocrine therapy in the neo/adjuvant setting

This study is being done to test the safety of lapatinib and trastuzumab with one of the following drugs: letrozole, anastrozole or exemestane (also called "aromatase inhibitor").


A Phase 1b/2 Randomized Study of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC)

This study is being done to find out what effects (good or bad) the combination of the experimental drug MEDI-573 and another kind of anticancer drug called an aromatase inhibitor (AI) has on you and your breast cancer.

Colorectal

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen

The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels and to find out what effects, good and/or bad, GS-6624 has on Colorectal Adenocarcinoma when it is given with another drug, FOLFIRI.

Kidney

An open-label, multicenter Phase 1b/2 study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment

This study will look at the effects of the drugs on your body, whether there is any shrinkage of your tumor, how long you live, and will also have laboratory tests to look at what happens to E7080 and everolimus in your body (how your body absorbs, distributes, breaks down and excretes (removes) these drugs).

Leukemia

A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)

This study is being done to find out how effective and safe vosaroxin in combination with cytarabine is compared with using cytarabine without vosaroxin.  The study will determine if survival is different between the two treatment groups.

Liver

A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant

PV-10 is a drug that is designed to be taken up primarily in tumor cells while quickly being cleared from the normal cells surrounding the tumor. This may allow PV-10 to kill the tumor while sparing healthy tissue around the tumor. In an attempt to keep as much of this drug as possible in the area of the tumor, PV-10 is directly injected into the tumor, where some of it remains for a period of time of up to several months or more.

Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC)

This study is being done to determine if ipilimumab, an investigational drug, in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel (Taxol®) and carboplatin (Paraplatin®) is safe and useful in subjects with lung cancer.

Lymphatic System

An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

This study is being done to determine whether the addition of VELCADE to a commonly used drug combination for patients with diffuse large B-Cell lymphoma called RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) benefits patients with non-GCB diffuse large B-cell lymphoma and whether this combination can be given safely.

Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

This study is being done to test the safety and effectiveness of a study drug called ofatumumab compared to a drug that is already approved to treat follicular lymphoma, named rituximab (also called Rituxan or Mabthera).

An Open-Label, Multicenter, Randomized, Phase III Study To Investigate The Efficacy And Safety Of Bendamustine Compared With Bendamustine + RO5072759 (GA101) In Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma

The purpose of this study is to compare the effects, good and/or bad, of the experimental drug GA101 given in combination with bendamustine compared with single-agent bendamustine on you and your indolent, CD20-positive, rituximab‑refractory NHL to find out which treatment is better. In this study, you will get either GA101 in combination with bendamustine or single-agent bendamustine.

Ovaries

A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/DOXIL®/CAELYX®) In Combination Versus PLD In Participants With Platinum-Resistant Ovarian Cancer

This study compares the combination of  Doxil® (pegylated liposomal doxorubicin) and EC145 against the combination of Doxil® (pegylated liposomal doxorubicin) and placebo.

Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer

The main purpose of this study is to measure length of time during and after treatment with MLN8237 in combination with paclitaxel or with paclitaxel alone that your disease responds or does not get worse.

Pancreas

A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

This study will compare the effects, good and/or bad, of the drug erlotinib in combination with gemcitabine to gemcitabine alone for people with pancreatic cancer that was removed by surgery to find out which is better.

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels. GS-6624 is an experimental drug being developed to treat many different diseases including myelofibrosis (a disease of the bone marrow in which collagen builds up fibrous scar tissue inside the marrow cavity).

Prostate

A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration resistant prostate cancer

The primary purpose of this study is to find out if cabozantinib is effective in reducing pain compared with mitoxantrone + prednisone. In order to see if cabozantinib is effective, your level of pain will be followed.

A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer

This study is being done to find out if being treated with cabazitaxel, prednisone and the experimental drug (custirsen) is better than cabazitaxel and prednisone alone at increasing survival in subjects with metastatic, castrate resistant prostate cancer.

A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with Castration-resistant Metastatic Prostate Cancer (CRMPC)

This study is being done to evaluate the safety, tolerability and anti-tumor activity of PSMA ADC in subjects with metastatic progressive castration-resistant prostate cancer (mCRPC). PSMA ADC belongs to a class of drugs called antibody-drug conjugates.

A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer

The purpose(s) of this study is to learn more about the occurrence of cerebrovascular events (more commonly known as "strokes") reported during or following sipuleucel-T therapy, and about the survival of all study participants.

Skin

Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node

This study is being done to find out if melanoma can be treated by removing only a few lymph nodes (called "sentinel nodes") from a lymph basin, a group of lymph nodes, (called a "sentinel node dissection"), or if all lymph nodes in a lymph basin must be removed (called a "complete lymph node dissection").

A Phase III Randomized Trial of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon alfa-2b for Resected High-Risk Melanoma

The purpose of this study is to compare the effects, good and/or bad, of Ipilimumab (given at 2 different doses, 10 mg/kg or 3 mg/kg) with interferon alfa-2b on you and your melanoma to find out which is better.

A Phase 3, Randomized Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma

This study is being done to determine if elotuzumab given with lenalidomide and dexamethasone is more effective in the initial treatment of multiple myeloma compared with a standard treatment of lenalidomide and dexamethasone alone.

A Phase 2 Biomarker Study of Elotuzumab (Humanized anti CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma

This study is being done to determine the effectiveness and safety of elotuzumab in patients with high risk smoldering myeloma. 

A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles

This study is being done to collect, store, catalog (putting the tissue and data in a tissue bank and data bank for later research purposes) and analyze blood and bone marrow samples and related health information from newly diagnosed multiple myeloma patients and then at different times during their disease.

Find a San Diego Oncologist

To find a Sharp-affiliated doctor, search for a San Diego oncologist or call 1-800-82-SHARP (1-800-827-4277), Monday through Friday, 8 am to 6 pm.

For More Cancer Care Information

If you think you may be interested in any of the trials listed, please consult with your physician or contact the clinical trials manager at 858-939-5062. To find general information about cancer, visit the Cancer Topics in Adult Health or read the Cancer News archive.